← Alvotech (ALVO) — catalysts, pipeline & price
Catalyst Dossier · compiled by CeliA 🧫
Alvotech (ALVO)
Biological Products, (No Diagnostic Substances) · market cap $1.8B · as of 2026-07-19
Research and calibrated estimates, not financial advice — verify before acting.
Next catalyst
2026-11-11 (est.)
Earnings
Pipeline
6
programs
Upcoming events
3
next 90d+
Dossier
Ready
cached
Alvotech (ALVO) is an Iceland-based biosimilar developer with ~1,012 employees and a market cap of roughly $1.24B at ~$3.46/share. The company operates an exclusively biosimilar pipeline spanning inflammation, oncology-adjacent ophthalmology, and bone health, with a near-term PDUFA for its vedolizumab biosimilar (AVT16) expected December 2026 and a pivotal Phase 3 readout for its high-dose aflibercept biosimilar (AVT29) expected mid-2027.
The catalyst path
- 2026-11-11 (est.)Earningsimp 5/10
- 2026-12-08 (est.)PDUFA · AVT16 (vedolizumab biosimilar)imp 8/10
- 2027-07-15 (est.)Phase 3 · AVT29 (proposed aflibercept HD biosimilar)imp 9/10
Pipeline
| Asset | Phase | Indication |
|---|---|---|
| AVT05 (proposed biosimilar to golimumab) | Phase 3 | Rheumatoid Arthritis |
| AVT03 | Phase 3 | Osteoporosis, Postmenopausal |
| Stelara | Phase 3 | Psoriasis |
| Adalimumab originator | Phase 3 | Plaque Psoriasis |
| AVT06 (proposed aflibercept biosimilar) | Phase 3 | Neovascular (Wet) AMD |
| AVT29 (proposed aflibercept HD biosimilar) | Phase 3 | Diabetic Macular Edema |
Price & technical context
3-month
+55.7%
6-month
+55.2%
12-month
-31.4%
52-wk range
$3.00–$8.98
vs 50-day MA
+19.9%
vs 200-day MA
+34.5%
Realized vol
80.0%
Max drawdown
-77.8%
Daily closes through 2026-10-01. Realized vol annualized; max drawdown over ~2 years.
The full dossier is a Pro feature
Thesis, bull & bear, the if-approved scenario, financials, smart-money signals and risks — compiled by CeliA. The catalyst path & pipeline above are free.
Sources & data
- SEC filings — EDGAR filings for ALVO (10-K, 10-Q, S-3, 13D/G, Form 4)
- Clinical trials — 6 registered trials on ClinicalTrials.gov (per-trial NCT links in the pipeline)
- Market & financial data — SEC EDGAR (XBRL filings, Form 4), Yahoo Finance, Nasdaq — prices, statements, key metrics, insider & institutional filings.
- Regulatory — openFDA, FDA advisory & PDUFA calendars.
Approval odds use historical phase base rates; the if-approved scenario is illustrative (see its note). Figures trace to the sources above — verify before acting.
Data from CatalystAlert (ClinicalTrials.gov, SEC EDGAR, openFDA, market-data providers). Compiled by CeliA. Not financial advice.